The drug information appearing in this column is for investigational drugs studied in clinical research protocols being pursued in the Clinical Center at the National Institutes of Health.
As with all investigational drugs, the drugs reported in this column have a Notice of Claimed Investigational Exemption for a New Drug (IND) assigned to them by the Food and Drug Administration (F.D.A.).
Get full access to this article
View all access options for this article.
References
1.
Merck Index, Eighth Edition, page 162.
2.
Protocol entitled, Relative Effects of Intravenous Bradykinin on the Respiratory System in Normal and Asthmatic Subjects, Newball, H. H., Reiser, H. R., NHLI, NIH, Bethesda, Md. 20014.
3.
BhoolaK. D., CollierH. O. J., SchacterM., and ShorleyP. G.: Brit. J. Pharmacol. Chemotherap.19: 190, 1962.
VaronierH. S., and PanzaniR.: The Effect of Inhalations of Bradykinin on Healthy and Atopic (Asthmatic) Children, Int. Arch. Allergy34: 293–296, 1968.
6.
FoxR. H.: Bradykinin as a Vasodilator in Man, J. Physiol.157, 589–602, 1961.
7.
BishopJ. M., HarrisP., and SegelN.: The Circulatory Effects of Bradykinin in Normal Subjects and Patients with Chronic Bronchitis, Brit. J. Pharmacol.25: 456–469, 1965.
8.
Cancer Chemotherapy Reports, Part 3, Vol. 1, No. 1, Dec. 1968.
9.
Protocol B133 entitled, Evaluation of a Combination of Adriamycin and Dibromodulcitol in Metastatic Breast Cancer, March 1973 (Medical Breast Cancer Service, Medical Oncology, NCI, NTH).
10.
Protocol entitled, Dibromodulcitol for Treatment of Refractory Acute Leukemia, Pediatric Oncology Branch, NCI, NIH, January 1971.
11.
Protocol entitled.Preliminary Clinical Trials with Dibromodulcitol, Phase MI, NCI, NIH, November 1968.
12.
HidakaH., NagatsuT., and TakeyaK.: Fusaric Acid, a Hypotensive Agent Produced by Fungi, J. Antibiot.22: 228 (5) 1969.
13.
Personal communication, Banyu Pharmaceutical Co. Ltd., Tokyo, Japan.
14.
Protocol entitled, Fusaric Acid Treatment of Parkinson's Disease and Related Disorders, Thomas N. Chase, M.D., Chief, Section on Experimental Therapeutics, LCS, NIMH, NIH, Bethesda, Maryland.
15.
HidakaH.: Fusaric (5-Butylpicolinic) Acid, an Inhibitor of Dopamine-β-Hydroxylase, Affects Serotonin and Noradrenalin, Nature231: 54, 1971.
16.
MattaR. J., and WootenG. F.: Pharmacology of Fusaric Acid in Man, Clin. Pharmacol. Ther.14: Number 4, Part 1, 1973.
